Clinical trials: Hair Problems
Androgenetic Alopecia
Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men
The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.
- Trial name
- NCT05636904
- Testing
- prostaglandin F2a analogue in vehicle solution high dose, prostaglandin F2a analogue in vehicle solution low dose, active ingredient-free vehicle solution to DLQ01
- Where
- 2 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Dermaliq Therapeutics, Inc.
Androgenic Alopecia, Female Pattern Hair Loss
Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy
This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solution and the Revian Red wireless smart cap, alone and in combination…
- Conditions
- Androgenic Alopecia, Female Pattern Hair Loss, Hair Loss
- Trial name
- KDKR26 (NCT07810504)
- Testing
- Scalp Stimulating Serum, Red Light Hair Growth Cap
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- K. Kay Durairaj, MD, FACS, A Medical Corporation
Telogen Effluvium
BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.
Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women.
- Trial name
- NCT04880889
- Testing
- BL 3000, Reference Pantogar
- Volunteers
- 326 people
- Sponsor
- Biolab Sanus Farmaceutica
Hair Thinning
Efficacy and Tolerability of a Scalp Serum
The goal of this clinical trial is to evaluate the efficacy and tolerability of a scalp serum on 60 healthy females aged 25 to 65 years with Fitzpatrick skin phototypes I-VI and with mild to moderate thinning hair.
- Trial name
- NCT07500623
- Testing
- Scalp Serum
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Revision Skincare
Alopecia, Androgenetic
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
- Trial name
- MONA (NCT07516561)
- Testing
- APSMNF 1, APSMNF 2, Eniagor®
- Where
- Brazil
- Volunteers
- 336 people
- Sponsor
- Apsen Farmaceutica S.A.
Hair Disease
AGA Biocellular Stem/Stromal Hair Regenerative Study
Purpose The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma…
- Trial name
- STRAAND (NCT02849470)
- Testing
- Intradermal Injection in hair loss, Platelet Rich Plasma, Adipose Derived Stem/Stromal Cells
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Healeon Medical Inc
Alopecia Totalis
Efalizumab in the Treatment of Alopecia, Phase II
Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.
- Trial name
- NCT00746980
- Testing
- efalizumab
- Sponsor
- Northwestern University
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Alopecia Areata
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be…
- Trial name
- NCT06564805
- Testing
- Candida Albicans Antigen Injection
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Androgenetic Alopecia, Exosomes
Exosome Treatment in Androgenetic Alopecia
This study aims to elucidate the effect of "foreskin-derived mesenchymal stromal cells derived exosome" injection into the scalp on hair density in patients with androgenetic alopecia and the contribution of this treatment on…
- Trial name
- NCT06539273
- Testing
- Exosome Complex, RNA
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Yeditepe University Hospital
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Androgenetic Alopecia
The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia
The purpose of this study is to evaluate the effect of autologous platelet-rich plasma (PRP) in the treatment of androgenetic alopecia.
- Trial name
- NCT03048461
- Testing
- Platelet Rich Plasma Prep System
- Sponsor
- Northwestern University
Lichen Planopilaris of Scalp, Alopecia Areata
Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias
The objective of this study is to assess the effect of standardized scalp care, specifically mechanical cleansing with the Venus Glow™ Device and water, on the scalp microbiome.
- Trial name
- NCT06357169
- Testing
- Venus Glow
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA)
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s).
- Conditions
- Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT06799520
- Testing
- VIS171
- Where
- 6 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alopecia Areata, Scarring Alopecia
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata
The primary objective of this study is to evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma…
- Trial name
- SAAA (NCT03078686)
- Testing
- tSVF by lipoaspiration, PRP Concentration, Emulsification tSVF
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Regeneris Medical
Androgenetic Alopecia
Comparison of Microneedling vs. Autologous Concentrated Growth Factor for the Treatment of Female Androgenetic Alopecia
Microneedling and autologous concentrated growth factor (CGF) have established their potential effect in inducing hair regrowth.
- Trial name
- NCT06218394
- Testing
- microneedling, Autologous Concentrated Growth Factor, 5% minoxidil
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Alopecia Areata
The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata
Alopecia areata is one of the most common cause of non-scarring alopecia. The pathogenesis is still unclear, however, it is believed to be an autoimmune disease.
- Trial name
- NCT00999869
- Testing
- Botulinum toxin type A, Triamcinolone acetonide
- Where
- 2 sites in Thailand
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Alopecia, Canities
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair
This will be a 6-month randomized, double-blind, placebo-controlled trial. A total of 152 participants with hair loss, including some with gray hair, will be enrolled and randomly assigned to four groups.
- Trial name
- NCT06998680
- Testing
- VitaGreen Capsule A+VitaGreen Tonic, VitaGreen Capsule B+VitaGreen Tonic
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vita Green Pharmaceutical (H.K.) Ltd.
Alopecia, Alopecia, Androgenetic
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01189279
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Allergan
Androgenetic Alopecia, Androgenic Alopecia
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density…
- Conditions
- Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair
- Trial name
- REBOOT-MEN (NCT04450589)
- Testing
- ALRV5XR, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Arbor Life Labs